Ovarian Cancer

After leaving an unsupportive support group for ovarian cancer, I finally found my pillars of support.

Having my omentum removed after an ovarian cancer diagnosis impacted my quality of life.

The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.

After my mom died at 50 years old, I was certain I wasn't going to reach 50. I'm glad I was wrong.

The Food and Drug Administration approved Tepylute — a liquid form of thiotepa — for the treatment of patients with breast or ovarian cancer.

Participating in research and leaning on advocacy organizations helped me through my rare cancer diagnosis.

Leaning on spiritual belief may strengthen patients' life purposes, but for many, it's common to temporarily loosen their grip on faith after a cancer diagnosis.

Seeing a young man ringing the bell surrounded by family reminded me of the incredible support I received during ovarian cancer, too.

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer.

Ignoring fear and anxiety only allows them to grow until they explode into a full-blown anxiety attack. It’s okay to be scared about cancer progression.

Even after surgery and chemotherapy, I make sure to shine through cancer and any fear that stares at me.

The Food and Drug Administration granted a full approval to Elahere for the treatment of certain patients with platinum-resistant gynecologic cancers.

My genetic testing covered 648 gene variants. Of course, researchers only know the significance of a fraction of those variants.

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

After my treatment ended for triple-negative breast cancer, I thought I was done with cancer — and then I was diagnosed with ovarian cancer.

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

As Anna “Chickadee” Cardwell from “Here Comes Honey Boo Boo” dies from cancer and former tennis player Chris Evert announces cancer diagnosis, here is what’s happening in the oncology space this week.

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

IRON, an artificial intelligence model, has an 80% accuracy rate of predicting therapy outcomes of patients with ovarian cancer.

A multidisciplinary surgical approach decreased death rates by 70% in patients with ovarian cancer.

From Suzanne Somers’ death from metastatic breast cancer and Julia Louis-Dreyfus discusses her outlook on life post-diagnosis, here is what’s happening in the oncology space this week.

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

Interim results of a trial displayed promising results for patients with ovarian cancer treated with IMNN-01 with neoadjuvant chemotherapy and a PARP inhibitor.

As Teddi Mellencamp reveals more about her cancer diagnosis and Shannen Doherty receives a standing ovation after her stage 4 cancer diagnosis, here’s what is happening in the oncology space this week.

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment.

Exercise was shown to reduce chemotherapy-induced peripheral neuropathy in ovarian cancer survivors, according to findings from a recent study.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.